- Home
- TPST vs LSTA Comparison
TPST vs LSTA Comparison
Compare TPST & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TPST | LSTA |
|---|---|---|
| Founded | 2011 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Misc Health and Biotechnology Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.1M | 16.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | TPST | LSTA |
|---|---|---|
| Price | $2.47 | $4.54 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | $10.00 | ★ $15.00 |
| AVG Volume (30 Days) | 90.3K | ★ 381.9K |
| Earning Date | 03-26-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $1,070,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.17 | $1.81 |
| 52 Week High | $12.48 | $4.89 |
Technical Indicators
Market Signals| Indicator | TPST | LSTA |
|---|---|---|
| Relative Strength Index (RSI) | 28.70 | 83.61 |
| Support Level | $2.55 | $4.48 |
| Resistance Level | $3.00 | $4.79 |
| Average True Range (ATR) | 0.23 | 0.17 |
| MACD | 0.00 | 0.09 |
| Stochastic Oscillator | 3.06 | 90.79 |
Price Performance
Historical ComparisonAbout TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.